Against the background of an increase in the incidence of COVID-19 around the world, the Russian Sputnik V vaccine is moving more and more confidently towards global recognition.
International banking circles already perceive the success of the third stage of clinical trials of the Russian vaccine as a significant stabilizing factor in the world market.
In its report, the Swiss investment bank Credit Suisse says, for example, that the drug is 92% effective, significantly higher than other vaccines currently undergoing clinical trials.
The vaccine developer is demonstrating unprecedented transparency in clinical trial data. The Sputnik V vaccine efficacy was 92% (calculated based on the distribution of 20 confirmed cases detected in the placebo group and in the group receiving the vaccine).
Currently, 40,000 volunteers are taking part in phase III, the double-blind, randomized, placebo-controlled clinical post-marketing study of the Sputnik V vaccine, of whom more than 20,000 volunteers have been vaccinated with the first dose of the vaccine and more than 16,000 volunteers with the first and second doses of the vaccine.
Credit Suisse claims that an additional factor for the market is the fact that NICEM vaccines. N.F. Gamaliel is a serious international brand, and the Institute's products have shown excellent results in the fight against Ebola and Middle East Respiratory Syndrome (MERS).
During the development of the drug, among other things, the possibility of its storage and delivery to remote regions of the world was also taken into account, which significantly increases its attractiveness as a drug.
It should be noted that RDIF, which has become a partner of the Gamaleya Institute for vaccine development, thanks to its international partners, ensures the production of more than 500 million doses of Sputnik V outside Russia - in India, China, South Korea, Brazil.
In its report, the Swiss investment bank Credit Suisse says, for example, that the drug is 92% effective, significantly higher than other vaccines currently undergoing clinical trials.
The Sputnik V vaccine, based on the use of a human adenoviral vector, has been demonstrated in clinical trials to develop long-term immunity to COVID-19.
The product of the Gamaleya Center uses injections of two vectors, rAd5 and rAd26, and this approach demonstrates high efficiency.The vaccine developer is demonstrating unprecedented transparency in clinical trial data. The Sputnik V vaccine efficacy was 92% (calculated based on the distribution of 20 confirmed cases detected in the placebo group and in the group receiving the vaccine).
Currently, 40,000 volunteers are taking part in phase III, the double-blind, randomized, placebo-controlled clinical post-marketing study of the Sputnik V vaccine, of whom more than 20,000 volunteers have been vaccinated with the first dose of the vaccine and more than 16,000 volunteers with the first and second doses of the vaccine.
Credit Suisse claims that an additional factor for the market is the fact that NICEM vaccines. N.F. Gamaliel is a serious international brand, and the Institute's products have shown excellent results in the fight against Ebola and Middle East Respiratory Syndrome (MERS).
During the development of the drug, among other things, the possibility of its storage and delivery to remote regions of the world was also taken into account, which significantly increases its attractiveness as a drug.
By the way, global Reuters writes about this today. The Sputnik V vaccine, manufactured in Russia, can be delivered anywhere in the world, as it can be stored in the so-called. lyophilized form, in other words, as a freeze-dried powder.
This design avoids the hassle of maintaining the cold chain that is required for vaccines from other manufacturers. According to the Lancet magazine, the greatest effect is observed in frozen vaccines (storage temperature from -18 to -20 degrees Celsius), as well as in freeze-dried vaccines (storage temperature from +2 to +8 degrees Celsius). In comparison, Pfizer products can be transported in temperatures as low as -70 degrees Celsius, which is costly to transport over long distances.It should be noted that RDIF, which has become a partner of the Gamaleya Institute for vaccine development, thanks to its international partners, ensures the production of more than 500 million doses of Sputnik V outside Russia - in India, China, South Korea, Brazil.